Global Allergy & Airways Patient Platform: Alpha-1 care must assess lung and liver together
In a LinkedIn post, the patient platform backed a call for reciprocal lung and liver assessment, multidisciplinary pathways and earlier testing in Alpha-1 Antitrypsin Deficiency.
“It took me more than 50 years to get diagnosed.”— Global Allergy & Airways Patient Platform
The Global Allergy & Airways Patient Platform wrote on LinkedIn that the Alpha-1 Lung and Liver Connection is calling for a fundamental shift in how Alpha-1 care is approached. The post opened with a patient's words: "It took me more than 50 years to get diagnosed." It described this as not an uncommon story in Alpha-1 Antitrypsin Deficiency.
The post set out four elements of the call: reciprocal assessment of both lung and liver involvement; multidisciplinary care pathways linking pulmonology, hepatology, genetics and primary care; and recognition of Alpha-1 as a multisystem genetic disorder rather than a single-organ condition. It also called for earlier testing in at-risk groups, namely people with COPD before age 45, bronchiectasis with no clear cause, unexplained liver disease, or a family history of Alpha-1.
The platform said earlier diagnosis and coordinated care can improve outcomes while supporting more efficient use of healthcare resources. It added that investing in diagnostic capacity and treatment access together, rather than as separate priorities, is essential.
The post used the hashtags #OneGeneTwoOrgansOneCommunity and #LookBothWays, and closed with the line: "Together, we are one community that looks both ways." It directed readers to gaapp.org/a1lungliver for more information.